Vitaxin applied molecular evolution.
Vitaxin is a humanized version of LM-609 (an mAb licensed from the Scripps Research Institute and Dr David Cheresh in May 1994, which blocks the integrin receptor, alpha v beta 3) [172038]. It is in phase II trials for the potential treatment of leiomyosarcoma [316471] and is also being studied in phase I trials as an anti-inflammatory and potential rheumatoid arthritis therapy [364031,313665]. Vitaxin and non-peptides are under evaluation for use in the treatment of other diseases in which vitronectin is reputed to play a role, e.g., arthritis, psoriasis and other inflammatory diseases. Patent positions are being established on these and other applications, as well as on the structure and use of the non-RGD proteins [182507].
Mikecz
K
K
Department of Orthopedic Surgery, Rush-Presbyterian-St Luke's Medical Center, 1653 West Congress Parkway, Chicago, IL 60612-3833, USA. kmikecz@rush.edu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D000075202:Contraindications; D015507:Drugs, Investigational / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D013329:Structure-Activity Relationship
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015507:Drugs, Investigational; C112567:etaracizumab